Compounds

Details Compounds Compounds

2006-12-21

2009-11-17

Shameem, Golam M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S301700, C548S302700, C548S304400, C548S309700, C514S385000, C514S393000

Reexamination Certificate

active

07618993

ABSTRACT:
The present invention relates to new compoundsor salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

REFERENCES:
patent: 3624103 (1971-11-01), De Martiis et al.
patent: 3839347 (1974-10-01), Fisher et al.
patent: 4722929 (1988-02-01), Austel et al.
patent: 4738981 (1988-04-01), Horwell
patent: 6794404 (2004-09-01), Beaulieu et al.
patent: 2003/0149050 (2003-08-01), Jagtap et al.
patent: 2003/0158188 (2003-08-01), Lee et al.
patent: 2004/0092569 (2004-05-01), Demaine et al.
patent: 2004/0152690 (2004-08-01), Balan et al.
patent: 2004/0248983 (2004-12-01), Morie et al.
patent: 2006/0205802 (2006-09-01), Liu et al.
patent: 2006/0287377 (2006-12-01), Besidski et al.
patent: 2007/0066586 (2007-03-01), Tokumasu et al.
patent: 2008/0015222 (2008-01-01), Besidski et al.
patent: 2300521 (1973-07-01), None
patent: 0149200 (1984-12-01), None
patent: 0419210 (1991-03-01), None
patent: 1312601 (2003-05-01), None
patent: 0882718 (2005-08-01), None
patent: 1186504 (1970-04-01), None
patent: 94/22859 (1994-10-01), None
patent: 99/00115 (1999-01-01), None
patent: 01/12189 (2001-02-01), None
patent: 01/85722 (2001-11-01), None
patent: 01/96336 (2001-12-01), None
patent: 02/50031 (2002-06-01), None
patent: 02/072536 (2002-09-01), None
patent: 02/085866 (2002-10-01), None
patent: 02/090326 (2002-11-01), None
patent: 02/100819 (2002-12-01), None
patent: 02/100822 (2002-12-01), None
patent: 03/014064 (2003-02-01), None
patent: 03/022809 (2003-03-01), None
patent: 03/027076 (2003-04-01), None
patent: 03/049702 (2003-06-01), None
patent: 03/053945 (2003-07-01), None
patent: 03/068749 (2003-08-01), None
patent: 2004/000828 (2003-12-01), None
patent: 2004/024154 (2004-03-01), None
patent: 2004/024710 (2004-03-01), None
patent: 2004100865 (2004-11-01), None
patent: 2004108712 (2004-12-01), None
patent: 2005021539 (2005-03-01), None
patent: 2005095327 (2005-10-01), None
patent: 2006033620 (2006-03-01), None
patent: 2008/018827 (2008-02-01), None
Gallard, et at., Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 18, No. 2. 2003,““New N-Pyridinyl (methyl)-N1-Substituted . . . Systemic anti-Inflammatory Agents””, pp. 201-208.
T.L. Gilchrist, “Heterocyclic Chemistry”, 2nd Edition, Longman Scientific andTechnical (1992), pp. 248-282.
Hwang, et al., “Hot Channels in Airways : Pharmacology of the Vanilloid Receptor”; Respiratory, Curr Opin Pharmacol 2002, June, 2(3) pp. 235-242.
Rashid, et al ., “Novel Expression of Vanilloid . . . in Neuropathic Pain”; J. Pharmacology & Experimental Therapeutics, vol. 304, No. 3, pp. 940-948, 2003.
Szallasi, et al . “Vanilloid (Capsaicin) Receptors in Health and Disease”; Am J Clin Pathot 2002, 118:110-121.
Tominaga, et al., “The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli” ; Neuron, 21:531-543 (1998).
Walker, et al ., “The VRI Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain”; J. Pharmacology & Experimental Therapeutics, vol. 304:56-62 (2003).
Yiangou, et al ., “Capsaicin Receptor VRI and ATP-Gated ion Channel P2X3, in Human Urinary Bladder”; BJU International (2001), 87, pp. 774-779.
Non-final Office Action mailed on Jan. 7, 2008, for U.S. Appl. No. 10/556,229, AstraZeneca.
Non-final office Action mailed on Jul. 16, 2007, for U.S. Appl. No. 10/556,229, AstraZeneca.
Co-pending U.S. Appl. No. 11/836,221, filed Aug. 9, 2007.
Non-final Office Action mailed on May 16, 2008, for U.S. Appl. No. 10/557,806, AstraZeneca.
Non-final Office Action mailed on Jul. 23, 2008 for U.S. Appl. No. 10/557,806, AstraZeneca.
Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291482, BRN 838602 abstract and Kamel et al, J. Prakt. Chem., vol. 31, 1966, pp. 100-105.
Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291483 BRN 926470 abstract and Osman: Kolor. ERT., vol. 11, 1969, p. 118.
Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291484 BRN 311062 abstract & Pinnow; Wiskott: Chem. Ber., vol. 32, 1899, p. 900.
Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291485 BRN 189489 abstract & Foster: J. Chem. Soc., 1957, pp. 4687-4688.
Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291490 BRN 326965 abstract & V. Walter; Kessler: J. Prak. Chem., vol. 2, No. 74, 1906, p. 198.
Kumar, et al., “Cyanoethylation of Benzimidazoles: Synthesis & Biological Activities of Some New 1-(beta-Cyanoethyl)benzimidazoles & Their Derivatives”, Indian Journal of Chemistry, Oct. 1985, vol. 24B, p. 1098-1101.
Lindberg, et al., “Long-Time Persistence of Superantigen-ProducingStaphylococcus aureusStrains in the Intestinal Microflora of Healthy Infants”, Pediatric Research 48:741-747 (2000).
McDonnell, et al ., 7-Hydroxynaphthalen-l-yt-Urea and -Amide Antagonists of Human Vanilloid Receptor 1; Bioorganic & Medicinal Chemistry Letters 14 (2004), pp. 531-534.
Musso, et al ., “Indanylidenes . 1 . Design and Synthesis of (E)-2-(4,6-Difluoro-1-indanylidene)acetamide, a Potent, Centrally Acting Muscle Relaxant with Antiinflammatory and Analgesic Activity”; J. Med. Client 2003, 46, pp. 399-408.
Patent Abstracts of Japan vol. 2000, No. 07, Sep. 29, 2000 & JP 2000 095767 A (Takeda Chem Ind Ltd), 4 Pril 2000.
Rudin, et al., “Staphylococcal Enterotoxin B and High Dose Phytohemagglutinin Induce a Th1- Skewed Response in Neonates Irrespective of Atopic Status at 2 Years of Age”, Scandinavian Journal of Immunology 52:415-461 (2000).
Sasaki, et al., “Prevention of collagen-induced arthritis with the superantigen Staphylococcal enterotoxin B”, Patho-physiology 4:25-31 (1997).
Soos, et al., “Treatment PL/J mice with the superantingen, staphylococcal enterotoxin B, prevents development of experimental allergic encephalomyelitis”, J Neuroimmunology 43:39-44 (1993).
Willitzer, H. et al., “Synthese und antivirale Wirsamkeit von substituierten 5-Ureido- und 5- Thioureidobenzimidazolderivaten” Pharmazie, VEB VERLAG VOLK und Gesundheit. Berlin, Germany vol. 33, No. 1, Jan. 1978 (1078-01), pp. 30-38, XP002209435 ISSN: 0031-7144 English Abstract is cited as access. No. 1978:424221.
STN International, File CAPLUS, accession No. 1978:424221, document No. 89:24221, Willitzer et al., “Synthesis and antiviral activity of substituted 5-ureido- and 5-thioureidobenzimidazole derivatives”, & Pharmazie (1978), 33(1) 30-8.
STN Intl. File CAPLUS, accession No. 1958:50566, doc No. 52-50566, Foster, R. “1-Ethyl-2-methyl-5-nitrobenzimidazole” & Journal of the Chem. Society, Abstracts (1957) 4687-8.
STN International , file CHEMCATS, Accession No. 2000:912544, Apr. 24, 2003, CHS 0297096, 1H-Benzimidazole-1-acetamide, N-[3-(trifluoromethyl)phenyl]-CAS Registry No. 294669-15-1.
STN International, file CHEMCATS, Accession No. 2000:532079, Apr. 23, 2003, BAS 0238979,1H-Benzimidazole-1-acetamide, N-(3-chlorophenyl)-CAS Registry No. 116488-26-7.
STN International, file CHEMCATS, Accession No. 2001:10738, Apr. 24, 2003, NS11937, 1H-Indole-3-butanamide, N-(4-methylphenyl)-CAS Registry No. 313550-48-0.
STN International, file CHEMCATS, Accession No. 2001:1505160, Apr. 29, 2003, AG-690/40696518,1H-Benzimidazole-l-acetamide, N-(2,3-dichlorophenyl)-, CAS Registry No. 332384-60-8.
STN International, file CHEMCATS, Accession No. 2002:2035573, Jul. 9, 2002, ASN 1816063,1H-Benzimidazole-l-acetamide, N-(3-chloro-4-methylphenyl)—CAS Registry No. 332908-87-9.
STN International, file CHEMCATS, Accession No. 2002:2042451, Jul. 9, 2002, ASN 4428244,1H-Benzimidazole-l-acetamide,N-(5-amnino-2-methylphenyl)—CAS registry No. 436095-70-4.
STN International, file CHEMCATS, Accession No. 2003 :454497

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4121790